insmed appoints roger adsett as chief commercial officer  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use  thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street insmed appoints roger adsett as chief commercial officer globenewswire sep    am edt bridgewater nj sept   globe newswire  insmed incorporated nasdaqinsm a global biopharmaceutical company focused on the unmet needs of patients with rare diseases today announced the appointment of roger adsett as chief commercial officer mr adsett was most recently senior vice president head of the gastrointestinal and internal medicine business unit at shire plc  as chief commercial officer and a member of insmeds senior leadership team mr adsett will be charged with overseeing the development and execution of insmeds global commercial strategy for arikayce™ liposomal amikacin for inhalation which is under development to treat patients with nontuberculous mycobacteria ntm lung infections mr adsett will be responsible for building and leading the commercial organization to ensure effective execution of brand development product launches and ongoing commercialization strategies including sales and marketing  roger is a seasoned executive with a proven track record of success in bringing therapies to market i am very pleased he will be joining insmed as we look forward to the commercialization of arikayce and additional products said will lewis president and chief executive officer of insmed  roger has extensive experience of ensuring optimal performance of marketed products and his global marketing expertise will be invaluable to our future as we prepare to become a commercialstage pharmaceutical company commenting on his appointment mr adsett said i am thrilled to have the opportunity to join insmed at such a promising time in the companys history i am looking forward to working with the talented team here to execute on the companys global strategy and to further its goal of meeting the unmet therapeutic needs of patients with ntm lung disease and other rare disorders prior to joining insmed mr adsett held various leadership roles with shire from  to  during his time as senior vice president of its gastrointestinal and internal medicine business unit mr adsett oversaw shires global commercial pl across six specialty and two rare disease brands previously he also served as shires gastrointestinal business unit leader responsible for building the global leading mesalamine business before joining shire mr adsett worked at astrazeneca for  years most recently serving as the global brand director for symbicort® a medicine for the treatment of asthma and chronic obstructive pulmonary disease prior to astrazeneca mr adsett was a senior analyst at accenture from  to   mr adsett holds an mba from the wharton school at the university of pennsylvania and a ba in english and economics from bucknell university if you liked this article you might like health sector down as report of industry price collusion surfaces the healthcare sector was dragged down by reports of price collusion and worsethanexpected thirdquarter profits vicky huang nov    pm edt biotech social media stocks are less frothy than janet yellen thinks a month after fed chair janet yellens comments etfs covering both groups are pushing towards new highs on strong fundamental backdrops andrew sachais aug    pm edt  stocks spiking on big volume unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst roberto pedone aug    am edt why insmed insm stock is plunging today insmed insm plunged monday after the company announced it would conduct two phase iii studies of its lead drug candidate arikayce which indicates a delay in its fda approval andrew meola aug    pm edt trending fords mustang is americas most popular classic car amds blowout second quarter got a boost from the cryptocurrency mining craze we found  products on amazon with inflated discount rates facebooks q results should make snap ceo evan spiegel wish he had accepted a b buyout offer advanced micro devices could explode another  within hours chart advertising partners  thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers insmed incorporated appoints roger adsett as chief commercial officer employer login post jobs job seeker login sign up search life sciences jobs search job title only radius miles km  news  news by subject  news by disease   news by date  search news get our freeindustry enewsletter email       insmed incorporated insm appoints roger adsett as chief commercial officer tweet   am   life sciences jobs     bullet newest jobs  last  hours   bullet california jobs   bullet massachusetts jobs   bullet new jersey jobs   bullet maryland jobs   bullet washington jobs   view more jobs bridgewater nj sept   globe newswire  insmed incorporated nasdaqinsm a global biopharmaceutical company focused on the unmet needs of patients with rare diseases today announced the appointment of roger adsett as chief commercial officer mr adsett was most recently senior vice president head of the gastrointestinal and internal medicine business unit at shire plc  as chief commercial officer and a member of insmed’s senior leadership team mr adsett will be charged with overseeing the development and execution of insmed’s global commercial strategy for arikayce™ liposomal amikacin for inhalation which is under development to treat patients with nontuberculous mycobacteria ntm lung infections mr adsett will be responsible for building and leading the commercial organization to ensure effective execution of brand development product launches and ongoing commercialization strategies including sales and marketing  “roger is a seasoned executive with a proven track record of success in bringing therapies to market i am very pleased he will be joining insmed as we look forward to the commercialization of arikayce and additional products” said will lewis president and chief executive officer of insmed  “roger has extensive experience of ensuring optimal performance of marketed products and his global marketing expertise will be invaluable to our future as we prepare to become a commercialstage pharmaceutical company” commenting on his appointment mr adsett said “i am thrilled to have the opportunity to join insmed at such a promising time in the company’s history i am looking forward to working with the talented team here to execute on the company’s global strategy and to further its goal of meeting the unmet therapeutic needs of patients with ntm lung disease and other rare disorders” prior to joining insmed mr adsett held various leadership roles with shire from  to  during his time as senior vice president of its gastrointestinal and internal medicine business unit mr adsett oversaw shire’s global commercial pl across six specialty and two rare disease brands previously he also served as shire’s gastrointestinal business unit leader responsible for building the global leading mesalamine business before joining shire mr adsett worked at astrazeneca for  years most recently serving as the global brand director for symbicort® a medicine for the treatment of asthma and chronic obstructive pulmonary disease prior to astrazeneca mr adsett was a senior analyst at accenture from  to   mr adsett holds an mba from the wharton school at the university of pennsylvania and a ba in english and economics from bucknell university insmed also announced the granting of an inducement award to mr adsett pursuant to nasdaq listing rule c mr adsett will receive an option to purchase shares of insmed common stock equivalent to the value of  as material inducement to entering into employment with the company the exact number of options will be determined using a blackscholes calculation based upon the closing price on the nasdaq global select market at the end of the day on the first business day of the month following his date of hire the agreement governing this option award will be consistent with insmed’s standard stock option inducement award agreement the options have a year term and will vest pursuant to insmed’s standard fouryear vesting schedule with  of the shares subject to the option award vesting on the first anniversary of his commencement of employment and  of the shares subject to the option award vesting on each sixmonth anniversary date thereafter through the fourth anniversary of the date of grant subject to mr adsett’s continued employment by insmed on each applicable vesting date the inducement grants were approved by insmed’s compensation committee on september   about insmed insmed incorporated is a global biopharmaceutical company focused on the unmet needs of patients with rare diseases the company is advancing a global phase  clinical study of arikayce liposomal amikacin for inhalation in nontuberculous mycobacteria ntm lung disease a rare and often chronic infection that is capable of causing irreversible lung damage and can be fatal there are currently no products indicated for the treatment of ntm lung disease in the united states or european union eu insmed’s earlierstage clinical pipeline includes ins a nebulized prodrug formulation of treprostinil that the company believes may offer a differentiated product profile with therapeutic potential in rare pulmonary disorders such as pulmonary arterial hypertension pah idiopathic pulmonary fibrosis ipf sarcoidosis and severe refractory asthma to complement its internal research insmed actively seeks inlicensing opportunities for a broad range of rare diseases  for more information visit wwwinsmedcom “insmed” and “arikayce” are the companys trademarks all other trademarks trade names or service marks appearing in this press release are the property of their respective owners forwardlooking statements this press release contains forward looking statements  “forwardlooking statements” as that term is defined in the private securities litigation reform act of  are statements that are not historical facts and involve a number of risks and uncertainties  words herein such as “may” “will” “should” “could” “would” “expects” “plans” “anticipates” “believes” “estimates” “projects” “predicts” “intends” “potential” “continues” and similar expressions as well as other words or expressions referencing future events conditions or circumstances identify forwardlooking statements forwardlooking statements are based upon the company’s current expectations and beliefs and involve known and unknown risks uncertainties and other factors which may cause actual results performance and achievements and the timing of certain events to differ materially from the results performance achievements or timing discussed projected anticipated or indicated in any forwardlooking statements such factors include among others the factors discussed in item a “risk factors” in the company’s annual report on form k for the year ended december   and subsequent quarterly reports on form q and the following the ability to complete development of receive regulatory approval for and successfully commercialize arikayce or liposomal amikacin for inhalation lai and ins nebulized treprostinil prodrug the number of patients enrolled and the timing of patient enrollment in the company’s global phase  clinical study of arikayce estimates of expenses and future revenues and profitability plans to develop and market new products and the timing of these development programs status timing and the results of preclinical studies and clinical trials and preclinical and clinical data described herein the sufficiency of preclinical and clinical data in obtaining regulatory approval for the company’s product candidates the timing of responses to information and data requests from the us food and drug administration the european medicines agency and other regulatory authorities clinical development of product candidates ability to obtain and maintain regulatory approval for product candidates expectation as to the timing of regulatory review and approval estimates regarding capital requirements and the needs for additional financing estimates of the size of the potential markets for product candidates selection and licensing of product candidates ability to attract third parties with acceptable development regulatory and commercialization expertise the benefits to be derived from corporate license agreements and other third party efforts including those relating to the development and commercialization of product candidates the degree of protection afforded to the company by its intellectual property portfolio the safety and efficacy of product candidates sources of revenues and anticipated revenues including contributions from license agreements and other third party efforts for the development and commercialization of products ability to create an effective direct sales and marketing infrastructure for products the company elects to market and sell directly the rate and degree of market acceptance of product candidates the impact of any litigation the company is a party to including without limitation the class action lawsuit recently filed against the company the timing scope and rate of reimbursement for product candidates the success of other competing therapies that may become available and the availability of adequate supply and manufacturing capacity and quality for product candidates the company cautions readers not to place undue reliance on any such forwardlooking statements which speak only as of the date they are made insmed disclaims any obligation except as specifically required by law and the rules of the securities and exchange commission to publicly update or revise any such statements to reflect any change in expectations or in events conditions or circumstances on which any such statements may be based or that may affect the likelihood that actual results will differ from those set forth in the forwardlooking statementsinsmed incorporated susan mesco head of investor relations  read at biospacecom related news insmed incorporated insm reports second quarter  financial results how mylan myl ceos mom helped boost epipen sales insmed incorporated insm reports second quarter  financial results the scientific advisors at theranos wont or cant talk insmed incorporated insm to participate at september investor conferences mylan myl ceo draws fire over use of private jet insmed incorporated insm announces upcoming presentations at european respiratory society  international congress meet the rock star scientist whos spending facebooks ceo and wifes  billion insmed incorporated insm to present at the piper jaffray th annual healthcare conference the bobblehead doll in the office of shire shpg ceo flemming ornskov please enable javascript to view the comments powered by disqus comments powered by disqus • biospacecom • insmed incorporated   • biotechpharma  personnel                 roger adsett executive profile  biography  bloomberg july    pm et biotechnology company overview of insmed incorporated snapshotpeople  overviewboard memberscommittees executive profile roger adsett chief commercial officer insmed incorporatedagetotal calculated compensationthis person is connected to  board members in  different organizations across  different industriessee board relationships background mr roger adsett has been chief commercial officer of insmed incorporated since september   mr adsett served as senior vice president and head of gastrointestinal and internal medicine business unit at shire plc since january  prior to that mr adsett served as senior vice president of gastrointestinal business unit leader at shire from august  to january  from october  to august  mr adsett served as general manager of oral ibd products  of the gastroenterology business unit of shire from november  to october  mr adsett held various marketing and commercial roles at astrazeneca plc a multinational pharmaceutical and biopharmaceutical company  astrazeneca  prior to his time at astrazeneca mr adsett was a senior analyst at accenture plc from september  to november  mr adsett serves as a director of shiremovetis nv mr adsett holds an mba from the wharton school at the university of pennsylvania and a ba in english and economics from bucknell universityread full background corporate headquarters building bridgewater new jersey united statesphone fax  board members memberships directorshiremovetis nv education ba bucknell universitymba university of pennsylvania  the wharton school other affiliations bucknell universityuniversity of pennsylvania  the wharton schoolshiremovetis nv annual compensation there is no annual compensation data available stocks options there is no stock options data available total compensation there is no total compensation data available request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup competitor compensationthere is no competitor compensation data available sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact insmed incorporated please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close roger adsett shire  pharmaceutical executive log inregister search this site this site include affiliate sites magazinecurrent issue digital edition issues archive topicsfrom the editor new and noteworthy strategy regulatory washington report sales  marketing europe global rd events resourceswebcasts podcasts videos whitepapers ebooks front  center sponsored blogs subscribe advertise contact us europe from the editor global new  noteworthy rd sales  marketing strategy   most read current issue top features new  noteworthy washington report webcasts share printerfriendly version send by email roger adsett shire jun   by pharmaceutical executive editors pharmaceutical executive roger adsett vp and general manager gastroenterology shire noted for strong leadership building blockbuster brandsvision explain it so others internalize—not recite—it roger adsett roger adsett knows big brands he cut his teeth at astra merck heading up marketing for nexium then moved to england to serve as global brand director for astrazenicas symbicort now resettled in the northeast corridor hes translating marketing savvy and global knowhow to shires gi business—with good results last years launch of lialda sent business soaring without cannibalizing pentasa sales shire brands now serve more than a quarter of the oral mesalamine market and with a copromotion deal signed with tap adsett will bring his blockbuster mindset to the realm of specialty sales nativex subscribe printdigital productslinkedin  twitter podcastswebcastsrss feed     compliance top of mind there is never a lack of legal or regulatory issues to keep track of—and worry about—in the life sciences industry the articles from pharmaceutical executive provide a look at the latest in compliance for marketing labeling and export control as well as offer tips to stay compliant in the coming years read more sponsored links contact us home advertise current issue subscribe enews subscribe twitter cbi conferences linkedin rss linking and rss policy privacy policy terms of use reprints applied clinical trials biopharm international lcgc  chromacademy nutritional outlook pharmaceutical technology spectroscopy   ubm all rights reserved lorem ipsum roger adsett insmed inc profile  biography  bloomberg feedback roger adsett chief commercial officer insmed inc career history chief commercial officer insmed inc present senior vpheadgastrointestinal shire plc unknown website wwwinsmedcom corporate information address  finderne avenue building  bridgewater nj  united states phone  fax  web url wwwinsmedcom from the web personal information education bucknell university bachelors degree university of pennsylvania mba sponsored financial commentaries more from the web home news top headlines most popular exclusive law entrepreneurs leaders economy environment science sports markets magazine pursuits magazine bloomberg visual data bloomberg best and worst for comments or complaints about news coverage click here regions us china europe asia uk  ireland australia  new zealand canada india  pakistan japan africa eastern europe latin america middle east markets commodities currencies bonds stocks energy markets municipal bonds emerging markets funds islamic finance industries energy technology real estate finance health care transportation insurance retail media manufacturing quick market data stocks stock futures world indexes americas europe middle east  africa asiapacific gainers  losers earnings calendar industry leaders currencies americas europe middle east  africa asiapacific foreign exchange cross rates fx fixings currency converter forex trading videos commodities energy prices metals prices agricultural prices rates  bonds us treasuries uk gilts germany bunds japan bonds australia bonds bloomberg bond indexes corporate bonds consumer rates economic calendar watchlist european debt crisis symbol search the market now personal finance top headlines saving  investing real estate retirement planning financial advisers taxes blog ventured  gained real cost of money gallery calculators watchlist portfolio tracker tech top headlines social media mobile  wireless web enterprise tech tv games  movies apple tech deals global tech slideshows videos us politics sustainability top headlines energy corporate sustainability policy natural resources health  population slideshows videos blog the grid luxury top headlines autos billionaires living property travel well spent loot blog pursuits magazine videos tv live tv channel finder personalities apple tv ipad app schedule us asia europe shows surveillance market makers lunch money street smart bloomberg west game changers video must see latest live tv shows playlist radio live radio shows schedule personalities podcasts bloomberg brief featured podcasts and new shows bloomberg view masters in business first word surveillance bloomberg advantage in the loop bloomberg law taking stock bloomberg best more podcasts blogs global tech the grid loot the market now political capital tech deals ventured and gained opinion my saved registration sign in bloombergcom businessweekcom company about blog careers diversity  inclusion news mission philanthropy  engagement press room procurement sustainability products financial products bloomberg professional service bloomberg anywhere bloomberg tradebook bloomberg briefs bloomberg indexes bloomberg sef service center customer support enterprise products enterprise solutions trading solutions industry products bloomberg bna bloomberg government bloomberg law bloomberg link bloomberg new energy finance bloomberg sports content licensing bloomberg anywhere mobile apps bloomberg visual data insmed appoints roger adsett as chief commercial officer skip to primary navigation skip to content skip to primary sidebar skip to secondary sidebarmain navigationinsmed appoints roger adsett as chief commercial officer insmed has appointed roger adsett a former global brand director for symbicort as its new chief commercial officer in preparation for commercialization of arikayce inhaled liposomal amikacin adsett also spent a portion of his time with astrazeneca overseeing global marketing strategy for rhinocort and rhinocort aqua he was most recently senior vp head of gastrointestinal and internal medicine business unit at shire arikayce is in phase  clinical development for the treatment of nontuberculous mycobacteria ntm lung disease in june  the company announced that it had withdrawn an maa for arkikayce that it had submitted to the eu in  saying that it would resubmit the application once it had data from an ongoing phase  trial insmed president and ceo will lewis commented “roger is a seasoned executive with a proven track record of success in bringing therapies to market i am very pleased he will be joining insmed as we look forward to the commercialization of arikayce and additional products roger has extensive experience of ensuring optimal performance of marketed products and his global marketing expertise will be invaluable to our future as we prepare to become a commercialstage pharmaceutical company” adsett said “i am thrilled to have the opportunity to join insmed at such a promising time in the company’s history i am looking forward to working with the talented team here to execute on the company’s global strategy and to further its goal of meeting the unmet therapeutic needs of patients with ntm lung disease and other rare disorders” read the insmed press release primary sidebarsign up for our free weekly newsletter enter email address now to subscribe email address eventsaugust september  european aerosol conference zurich switzerland august august  ddf summit boston ma september september  inhalation asia  macau september september  rd workshop on pulmonary drug delivery istanbul turkey october october  aerosol school hamilton on canada see all upcoming events secondary sidebarsuppliers capsules and blisters consultants contract research contract manufacturing devices education excipients filling equipment instruments particle manufacturing software and modeling follow us on twitter insmed appoints roger adsett as chief commercial officer  pg  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use  thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street insmed appoints roger adsett as chief commercial officer globenewswire sep    am edt forwardlooking statements this press release contains forward looking statements  forwardlooking statements as that term is defined in the private securities litigation reform act of  are statements that are not historical facts and involve a number of risks and uncertainties  words herein such as may will should could would expects plans anticipates believes estimates projects predicts intends potential continues and similar expressions as well as other words or expressions referencing future events conditions or circumstances identify forwardlooking statements forwardlooking statements are based upon the companys current expectations and beliefs and involve known and unknown risks uncertainties and other factors which may cause actual results performance and achievements and the timing of certain events to differ materially from the results performance achievements or timing discussed projected anticipated or indicated in any forwardlooking statements such factors include among others the factors discussed in item a risk factors in the companys annual report on form k for the year ended december   and subsequent quarterly reports on form q and the following the ability to complete development of receive regulatory approval for and successfully commercialize arikayce or liposomal amikacin for inhalation lai and ins nebulized treprostinil prodrug the number of patients enrolled and the timing of patient enrollment in the companys global phase  clinical study of arikayce estimates of expenses and future revenues and profitability plans to develop and market new products and the timing of these development programs status timing and the results of preclinical studies and clinical trials and preclinical and clinical data described herein the sufficiency of preclinical and clinical data in obtaining regulatory approval for the companys product candidates the timing of responses to information and data requests from the us food and drug administration the european medicines agency and other regulatory authorities clinical development of product candidates ability to obtain and maintain regulatory approval for product candidates expectation as to the timing of regulatory review and approval estimates regarding capital requirements and the needs for additional financing estimates of the size of the potential markets for product candidates selection and licensing of product candidates ability to attract third parties with acceptable development regulatory and commercialization expertise the benefits to be derived from corporate license agreements and other third party efforts including those relating to the development and commercialization of product candidates the degree of protection afforded to the company by its intellectual property portfolio the safety and efficacy of product candidates sources of revenues and anticipated revenues including contributions from license agreements and other third party efforts for the development and commercialization of products ability to create an effective direct sales and marketing infrastructure for products the company elects to market and sell directly the rate and degree of market acceptance of product candidates the impact of any litigation the company is a party to including without limitation the class action lawsuit recently filed against the company the timing scope and rate of reimbursement for product candidates the success of other competing therapies that may become available and the availability of adequate supply and manufacturing capacity and quality for product candidates the company cautions readers not to place undue reliance on any such forwardlooking statements which speak only as of the date they are made insmed disclaims any obligation except as specifically required by law and the rules of the securities and exchange commission to publicly update or revise any such statements to reflect any change in expectations or in events conditions or circumstances on which any such statements may be based or that may affect the likelihood that actual results will differ from those set forth in the forwardlooking statements insmed incorporatedsusan mescohead of investor relations if you liked this article you might like health sector down as report of industry price collusion surfaces the healthcare sector was dragged down by reports of price collusion and worsethanexpected thirdquarter profits vicky huang nov    pm edt biotech social media stocks are less frothy than janet yellen thinks a month after fed chair janet yellens comments etfs covering both groups are pushing towards new highs on strong fundamental backdrops andrew sachais aug    pm edt  stocks spiking on big volume unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst roberto pedone aug    am edt why insmed insm stock is plunging today insmed insm plunged monday after the company announced it would conduct two phase iii studies of its lead drug candidate arikayce which indicates a delay in its fda approval andrew meola aug    pm edt trending fords mustang is americas most popular classic car amds blowout second quarter got a boost from the cryptocurrency mining craze we found  products on amazon with inflated discount rates facebooks q results should make snap ceo evan spiegel wish he had accepted a b buyout offer advanced micro devices could explode another  within hours chart advertising partners  thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers insmed inc via public  insmed appoints roger adsett as chief commercial officer hello   united states  news international news education environment healthcare technology internet science social and nonprofit local news politicsand policy government politics local government international policy businessand economy economy finance stock markets jobs and labor company news industry news aerospace agriculture chemicals commodities construction consumer electronics defense energy nuclear energy oil and gas renewable energy financial services banking insurance fishing and aquaculture manufacturing information technology metals and mining pharmaceuticals and biotechnology real estate professional and business services legal telecommunications tobacco retail transportation air transportation maritime transportation rail transportation road transportation utilities forestry and wood industry artsand culture art books and literature entertainment cinema media radio and television music lifestyleand leisure automotive home and garden fashion and luxury clothing and textile food travel and hospitality boating and yachting sports baseball basketball boxing cricket cycling football american football australian football soccer golf hockey racing rugby sailing skiing and winter sports tennis volleyball noodls browser compatibility check the security settings of your browser are blocking the execution of scripts to use noodls javascript support must be enabled please change your browsers security settings to enable javascript if you have changed your browsers security settings you can click here related announcements science mallinckrodt plc mallinckrodt posts data from legacy hp acthar® gel repository oda  oregon department of agriculture oda orders stop sale and removal order on azatin o pesticide product oda  oregon department of agriculture oda orders stop sale and removal order on neemix  pesticide product more company news best buy co inc hubert joly signs ceo pledge for diversity and inclusion mta  metropolitan transportation mta chairman joseph lhota unveils new york city subway action plan mta  metropolitan transportation statement from former mayor david n dinkins more search insmed inc   press release  distributed by public on   insmed appoints roger adsett as chief commercial officer bridgewater nj sept   globe newswire  insmed incorporated nasdaqinsm a global biopharmaceutical company focused on the unmet needs of patients with rare diseases today announced the appointment of roger adsett as chief commercial officer mr adsett was most recently senior vice president head of the gastrointestinal and internal medicine business unit at shire plc as chief commercial officer and a member of insmeds senior leadership team mr adsett will be charged with overseeing the development and execution of insmeds global commercial strategy for arikayce™ liposomal amikacin for inhalation which is under development to treat patients with nontuberculous mycobacteria ntm lung infections mr adsett will be responsible for building and leading the commercial organization to ensure effective execution of brand development product launches and ongoing commercialization strategies including sales and marketing roger is a seasoned executive with a proven track record of success in bringing therapies to market i am very pleased he will be joining insmed as we look forward to the commercialization of arikayce and additional products said will lewis president and chief executive officer of insmed roger has extensive experience of ensuring optimal performance of marketed products and his global marketing expertise will be invaluable to our future as we prepare to become a commercialstage pharmaceutical company commenting on his appointment mr adsett said i am thrilled to have the opportunity to join insmed at such a promising time in the companys history i am looking forward to working with the talented team here to execute on the companys global strategy and to further its goal of meeting the unmet therapeutic needs of patients with ntm lung disease and other rare disorders prior to joining insmed mr adsett held various leadership roles with shire from  to  during his time as senior vice president of its gastrointestinal and internal medicine business unit mr adsett oversaw shires global commercial pl across six specialty and two rare disease brands previously he also served as shires gastrointestinal business unit leader responsible for building the global leading mesalamine business before joining shire mr adsett worked at astrazeneca for  years most recently serving as the global brand director for symbicort® a medicine for the treatment of asthma and chronic obstructive pulmonary disease prior to astrazeneca mr adsett was a senior analyst at accenture from  to  mr adsett holds an mba from the wharton school at the university of pennsylvania and a ba in english and economics from bucknell university insmed also announced the granting of an inducement award to mr adsett pursuant to nasdaq listing rule c mr adsett will receive an option to purchase shares of insmed common stock equivalent to the value of  as material inducement to entering into employment with the company the exact number of options will be determined using a blackscholes calculation based upon the closing price on the nasdaq global select market at the end of the day on the first business day of the month following his date of hire the agreement governing this option award will be consistent with insmeds standard stock option inducement award agreement the options have a year term and will vest pursuant to insmeds standard fouryear vesting schedule with  of the shares subject to the option award vesting on the first anniversary of his commencement of employment and  of the shares subject to the option award vesting on each sixmonth anniversary date thereafter through the fourth anniversary of the date of grant subject to mr adsetts continued employment by insmed on each applicable vesting date the inducement grants were approved by insmeds compensation committee on september   about insmed insmed incorporated is a global biopharmaceutical company focused on the unmet needs of patients with rare diseases the company is advancing a global phase  clinical study of arikayce liposomal amikacin for inhalation in nontuberculous mycobacteria ntm lung disease a rare and often chronic infection that is capable of causing irreversible lung damage and can be fatal there are currently no products indicated for the treatment of ntm lung disease in the united states or european union eu insmeds earlierstage clinical pipeline includes ins a nebulized prodrug formulation of treprostinil that the company believes may offer a differentiated product profile with therapeutic potential in rare pulmonary disorders such as pulmonary arterial hypertension pah idiopathic pulmonary fibrosis ipf sarcoidosis and severe refractory asthma to complement its internal research insmed actively seeks inlicensing opportunities for a broad range of rare diseases for more information visit wwwinsmedcom insmed and arikayce are the companys trademarks all other trademarks trade names or service marks appearing in this press release are the property of their respective owners forwardlooking statements this press release contains forward looking statements forwardlooking statements as that term is defined in the private securities litigation reform act of  are statements that are not historical facts and involve a number of risks and uncertainties words herein such as may will should could would expects plans anticipates believes estimates projects predicts intends potential continues and similar expressions as well as other words or expressions referencing future events conditions or circumstances identify forwardlooking statements forwardlooking statements are based upon the companys current expectations and beliefs and involve known and unknown risks uncertainties and other factors which may cause actual results performance and achievements and the timing of certain events to differ materially from the results performance achievements or timing discussed projected anticipated or indicated in any forwardlooking statements such factors include among others the factors discussed in item a risk factors in the companys annual report on form k for the year ended december   and subsequent quarterly reports on form q and the following the ability to complete development of receive regulatory approval for and successfully commercialize arikayce or liposomal amikacin for inhalation lai and ins nebulized treprostinil prodrug the number of patients enrolled and the timing of patient enrollment in the companys global phase  clinical study of arikayce estimates of expenses and future revenues and profitability plans to develop and market new products and the timing of these development programs status timing and the results of preclinical studies and clinical trials and preclinical and clinical data described herein the sufficiency of preclinical and clinical data in obtaining regulatory approval for the companys product candidates the timing of responses to information and data requests from the us food and drug administration the european medicines agency and other regulatory authorities clinical development of product candidates ability to obtain and maintain regulatory approval for product candidates expectation as to the timing of regulatory review and approval estimates regarding capital requirements and the needs for additional financing estimates of the size of the potential markets for product candidates selection and licensing of product candidates ability to attract third parties with acceptable development regulatory and commercialization expertise the benefits to be derived from corporate license agreements and other third party efforts including those relating to the development and commercialization of product candidates the degree of protection afforded to the company by its intellectual property portfolio the safety and efficacy of product candidates sources of revenues and anticipated revenues including contributions from license agreements and other third party efforts for the development and commercialization of products ability to create an effective direct sales and marketing infrastructure for products the company elects to market and sell directly the rate and degree of market acceptance of product candidates the impact of any litigation the company is a party to including without limitation the class action lawsuit recently filed against the company the timing scope and rate of reimbursement for product candidates the success of other competing therapies that may become available and the availability of adequate supply and manufacturing capacity and quality for product candidates the company cautions readers not to place undue reliance on any such forwardlooking statements which speak only as of the date they are made insmed disclaims any obligation except as specifically required by law and the rules of the securities and exchange commission to publicly update or revise any such statements to reflect any change in expectations or in events conditions or circumstances on which any such statements may be based or that may affect the likelihood that actual results will differ from those set forth in the forwardlooking statements insmed incorporated susan mesco head of investor relations  source insmed incorporated news provided by acquire media sharing and personal tools please select the service you want to use newsvine digg delicious stumbleupon technorati buzz favorites google reader public link please use the above public link if you want to share this noodl on another website close smartlinks  insmed inc  science  research  company news  business announcements  company appointments  products and services  manufacturing  pharmaceuticals  professional and business services  pharmaceutical companies  nasdaq  börse frankfurt  börse berlin  back  view original format copyright  public technologies inc  privacy policy  terms of use  contact roger adsett  shire plc  zoominfocom microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft background checks and public records search  truthfinder call toll free   public records search social media photos police records background checks contact information and much more start here  try searching a friend relative celebrity yourself or someone else you might know first name last name city state all states alabama alaska arizona arkansas california colorado connecticut district of columbia delaware florida georgia hawaii idaho illinois indiana iowa kansas kentucky louisiana maine maryland massachusetts michigan minnesota mississippi missouri montana nebraska nevada new hampshire new jersey new mexico new york north carolina north dakota ohio oklahoma oregon pennsylvania rhode island south carolina south dakota tennessee texas utah vermont virgin islands virginia washington west virginia wisconsin wyoming this is me searching for yourself search this secure connection is confirmed were very popular what our happy users are saying truthfindercom is freakishly accurate… really scary how much info is out there zac k you found an old friend for me thank you nancy v truthfinder is an excellent site for finding out about someone sherrie f this site is so wonderful i found my lost godchildren and their mom thank you so much lawrence w this is one way to really know a potential date charmaine r your service is more than perfect it is a blessing thank you for the very hard work that you do richard b truthfinder is a very accurate updated system their information is proper and can be very helpful too juan m notice this site contains real police records court records of driving citations speeding tickets felonies misdemeanors sexual offenses mugshots etc background reports photos court documents address information phone numbers and much more please be careful when conducting a search and ensure all the information you enter is accurate learning the truth about the history of your family and friends can be shocking so please be cautious when using this tool truthfinder does not provide consumer reports and is not a consumer reporting agency we provide a lot of sensitive information that can be used to satisfy your curiosity protect your family and find the truth about the people in your life you may not use our service or the information it provides to make decisions about consumer credit employers insurance tenant screening or any other purposes that would require fcra compliance i understand help us refine your results select your gender male female next skip background checks and public records search  truthfinder call toll free   public records search social media photos police records background checks contact information and much more start here  try searching a friend relative celebrity yourself or someone else you might know first name last name city state all states alabama alaska arizona arkansas california colorado connecticut district of columbia delaware florida georgia hawaii idaho illinois indiana iowa kansas kentucky louisiana maine maryland massachusetts michigan minnesota mississippi missouri montana nebraska nevada new hampshire new jersey new mexico new york north carolina north dakota ohio oklahoma oregon pennsylvania rhode island south carolina south dakota tennessee texas utah vermont virgin islands virginia washington west virginia wisconsin wyoming this is me searching for yourself search this secure connection is confirmed were very popular what our happy users are saying truthfindercom is freakishly accurate… really scary how much info is out there zac k you found an old friend for me thank you nancy v truthfinder is an excellent site for finding out about someone sherrie f this site is so wonderful i found my lost godchildren and their mom thank you so much lawrence w this is one way to really know a potential date charmaine r your service is more than perfect it is a blessing thank you for the very hard work that you do richard b truthfinder is a very accurate updated system their information is proper and can be very helpful too juan m notice this site contains real police records court records of driving citations speeding tickets felonies misdemeanors sexual offenses mugshots etc background reports photos court documents address information phone numbers and much more please be careful when conducting a search and ensure all the information you enter is accurate learning the truth about the history of your family and friends can be shocking so please be cautious when using this tool truthfinder does not provide consumer reports and is not a consumer reporting agency we provide a lot of sensitive information that can be used to satisfy your curiosity protect your family and find the truth about the people in your life you may not use our service or the information it provides to make decisions about consumer credit employers insurance tenant screening or any other purposes that would require fcra compliance i understand help us refine your results select your gender male female next skip background checks and public records search  truthfinder call toll free   public records search social media photos police records background checks contact information and much more start here  try searching a friend relative celebrity yourself or someone else you might know first name last name city state all states alabama alaska arizona arkansas california colorado connecticut district of columbia delaware florida georgia hawaii idaho illinois indiana iowa kansas kentucky louisiana maine maryland massachusetts michigan minnesota mississippi missouri montana nebraska nevada new hampshire new jersey new mexico new york north carolina north dakota ohio oklahoma oregon pennsylvania rhode island south carolina south dakota tennessee texas utah vermont virgin islands virginia washington west virginia wisconsin wyoming this is me searching for yourself search this secure connection is confirmed were very popular what our happy users are saying truthfindercom is freakishly accurate… really scary how much info is out there zac k you found an old friend for me thank you nancy v truthfinder is an excellent site for finding out about someone sherrie f this site is so wonderful i found my lost godchildren and their mom thank you so much lawrence w this is one way to really know a potential date charmaine r your service is more than perfect it is a blessing thank you for the very hard work that you do richard b truthfinder is a very accurate updated system their information is proper and can be very helpful too juan m notice this site contains real police records court records of driving citations speeding tickets felonies misdemeanors sexual offenses mugshots etc background reports photos court documents address information phone numbers and much more please be careful when conducting a search and ensure all the information you enter is accurate learning the truth about the history of your family and friends can be shocking so please be cautious when using this tool truthfinder does not provide consumer reports and is not a consumer reporting agency we provide a lot of sensitive information that can be used to satisfy your curiosity protect your family and find the truth about the people in your life you may not use our service or the information it provides to make decisions about consumer credit employers insurance tenant screening or any other purposes that would require fcra compliance i understand help us refine your results select your gender male female next skip background checks and public records search  truthfinder call toll free   public records search social media photos police records background checks contact information and much more start here  try searching a friend relative celebrity yourself or someone else you might know first name last name city state all states alabama alaska arizona arkansas california colorado connecticut district of columbia delaware florida georgia hawaii idaho illinois indiana iowa kansas kentucky louisiana maine maryland massachusetts michigan minnesota mississippi missouri montana nebraska nevada new hampshire new jersey new mexico new york north carolina north dakota ohio oklahoma oregon pennsylvania rhode island south carolina south dakota tennessee texas utah vermont virgin islands virginia washington west virginia wisconsin wyoming we also search social networks this is me searching for yourself search this secure connection is confirmed were very popular what our happy users are saying truthfindercom is freakishly accurate… really scary how much info is out there zac k you found an old friend for me thank you nancy v truthfinder is an excellent site for finding out about someone sherrie f this site is so wonderful i found my lost godchildren and their mom thank you so much lawrence w this is one way to really know a potential date charmaine r your service is more than perfect it is a blessing thank you for the very hard work that you do richard b truthfinder is a very accurate updated system their information is proper and can be very helpful too juan m notice this site contains real police records court records of driving citations speeding tickets felonies misdemeanors sexual offenses mugshots etc background reports photos court documents address information phone numbers and much more please be careful when conducting a search and ensure all the information you enter is accurate learning the truth about the history of your family and friends can be shocking so please be cautious when using this tool truthfinder does not provide consumer reports and is not a consumer reporting agency we provide a lot of sensitive information that can be used to satisfy your curiosity protect your family and find the truth about the people in your life you may not use our service or the information it provides to make decisions about consumer credit employers insurance tenant screening or any other purposes that would require fcra compliance i understand help us refine your results select your gender male female next skip background checks and public records search  truthfinder call toll free   public records search social media photos police records background checks contact information and much more start here  try searching a friend relative celebrity yourself or someone else you might know first name last name city state all states alabama alaska arizona arkansas california colorado connecticut district of columbia delaware florida georgia hawaii idaho illinois indiana iowa kansas kentucky louisiana maine maryland massachusetts michigan minnesota mississippi missouri montana nebraska nevada new hampshire new jersey new mexico new york north carolina north dakota ohio oklahoma oregon pennsylvania rhode island south carolina south dakota tennessee texas utah vermont virgin islands virginia washington west virginia wisconsin wyoming this is me searching for yourself search this secure connection is confirmed were very popular what our happy users are saying truthfindercom is freakishly accurate… really scary how much info is out there zac k you found an old friend for me thank you nancy v truthfinder is an excellent site for finding out about someone sherrie f this site is so wonderful i found my lost godchildren and their mom thank you so much lawrence w this is one way to really know a potential date charmaine r your service is more than perfect it is a blessing thank you for the very hard work that you do richard b truthfinder is a very accurate updated system their information is proper and can be very helpful too juan m notice this site contains real police records court records of driving citations speeding tickets felonies misdemeanors sexual offenses mugshots etc background reports photos court documents address information phone numbers and much more please be careful when conducting a search and ensure all the information you enter is accurate learning the truth about the history of your family and friends can be shocking so please be cautious when using this tool truthfinder does not provide consumer reports and is not a consumer reporting agency we provide a lot of sensitive information that can be used to satisfy your curiosity protect your family and find the truth about the people in your life you may not use our service or the information it provides to make decisions about consumer credit employers insurance tenant screening or any other purposes that would require fcra compliance i understand help us refine your results select your gender male female next skip